Clinical Trials Logo

Clinical Trial Summary

The lysosome is a specialized part of the cell that functions to degrade metabolic wastes in the cell. Defects in the functioning of the lysosome result in accumulation and subsequent storage of such metabolic wastes. These defects lead to conditions known as lysosomal storage diseases (LSD). LSDs are caused by inherited genetic mutations and there are over 40 genetically distinct lysosomal storage diseases. Within each specific lysosomal storage disease there are variances in severity of disease, age of onset, and clinical presentation. Though the genetic mutations contributing to the disease have been largely clarified, the molecular and cellular mechanisms that contribute to variations in each distinct LSD remain unclear. With this study we intend to better understand at the cellular and molecular level how the accumulation and storage of metabolic wastes in the lysosome affect the clinical manifestation of LSDs, to detect changes in these mechanisms upon treatment administration, and to correlate these results to genetic information. The knowledge obtained from this research study could lead to better ways to diagnose and treat lysosomal storage diseases.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02000310
Study type Observational
Source O & O Alpan LLC
Contact Ozlem Goker-Alpan, MD
Phone 571-308-1904
Email ogoker-alpan@ldrtc.org
Status Recruiting
Phase
Start date November 2013
Completion date December 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT00001215 - Genetic Studies of Lysosomal Storage Disorders
Terminated NCT00654433 - ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Phase 3
Recruiting NCT02120235 - Investigating Lysosomal Storage Diseases in Minority Groups N/A